Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma

Fig. 6

Inhibition of IRAK1 attenuates tumor growth in subcutaneous HCC models. a Xenografted tumor of SMMU-7721 cell lines stably transfected with lentivirus-delivering shRNA for IRAK1 (shIRAK2) in nude mice. b The graph shows changes in the volume or weight of tumors. The data are the mean ± SE (n = 4). c The Ki67 staining of Xenografted tumor (X100 and X200). d The graph shows changes in the volumes or weights of tumors. The data are the mean ± SE (n = 4). SMMU-7721 cell lines were implanted subcutaneously in mice and allowed to grow until the tumors reached a size of approximately 150 mm3. Xenografted mice were randomized and injected i.p. with 2.12 mg/kg IRAK1/4 inhibitor 4 times per week. Two weeks later, the average tumor volumes and weights of the IRAK1/4 inhibitor group were analyzed comparing with the control group. Tumor volumes from two groups were analyzed by two-way ANOVA analysis (*p < 0.05). The graph shows individual tumor volume (t-test, *p < 0.05)

Back to article page